Company intelligence / Profile preview

Definitive Diagnostics

New York, New York, United Statesdefinitivedx.bio ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

In early lab testing on 273 patients, the company’s blood test for breast and other cancers demonstrated 99% sensitivity and nearly 97% specificity, including at Stage I for breast cancer. Similar results were observed in lung, colorectal, ovarian, and pancreatic cancers. The technology aims to reduce false positives by up to 90%, potentially eliminating unnecessary biopsies and costly follow-up tests.

Therapeutic areas: Oncology
Modalities: Protein biomarker assayLiquid biopsyAI-enhanced diagnostic platform
Industry: Protein Biomarker Diagnostics

Partnerships

Hamilton CorpThermo Fisher ScientificWashington University Medical School Core LaboratoriesUniversity of Kansas Medical Center Department of Science and Biostatistics

Beyond the preview

Go deeper on Definitive Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Definitive Diagnostics.

Explore the full profile